Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 71 | 2025 | 1127 | 12.010 |
Why?
|
Brain Ischemia | 51 | 2024 | 399 | 11.300 |
Why?
|
Leukoaraiosis | 13 | 2019 | 44 | 5.860 |
Why?
|
Thrombectomy | 22 | 2025 | 208 | 4.450 |
Why?
|
Brain Injuries, Traumatic | 7 | 2025 | 84 | 4.170 |
Why?
|
White Matter | 7 | 2020 | 114 | 3.680 |
Why?
|
Tissue Plasminogen Activator | 13 | 2024 | 125 | 3.220 |
Why?
|
Endovascular Procedures | 25 | 2025 | 609 | 3.090 |
Why?
|
Atrial Fibrillation | 15 | 2024 | 805 | 3.080 |
Why?
|
Infarction, Middle Cerebral Artery | 17 | 2019 | 70 | 2.960 |
Why?
|
Severity of Illness Index | 19 | 2024 | 1479 | 2.830 |
Why?
|
Thrombolytic Therapy | 15 | 2025 | 184 | 2.800 |
Why?
|
Retrospective Studies | 64 | 2025 | 6071 | 2.670 |
Why?
|
Fibrinolytic Agents | 13 | 2025 | 163 | 2.650 |
Why?
|
Cerebrovascular Circulation | 18 | 2024 | 174 | 2.580 |
Why?
|
Male | 120 | 2025 | 27749 | 2.500 |
Why?
|
Intracranial Hemorrhages | 8 | 2024 | 61 | 2.430 |
Why?
|
Aged | 79 | 2025 | 13408 | 2.410 |
Why?
|
Aged, 80 and over | 49 | 2025 | 5119 | 2.390 |
Why?
|
Anticoagulants | 15 | 2025 | 480 | 2.350 |
Why?
|
Brain Concussion | 4 | 2023 | 28 | 2.220 |
Why?
|
Treatment Outcome | 57 | 2025 | 5283 | 2.200 |
Why?
|
Middle Aged | 74 | 2025 | 16314 | 2.010 |
Why?
|
Disease Models, Animal | 21 | 2025 | 2050 | 1.940 |
Why?
|
Embolism | 6 | 2020 | 39 | 1.940 |
Why?
|
Cerebral Infarction | 10 | 2022 | 76 | 1.860 |
Why?
|
Brain | 21 | 2023 | 1488 | 1.850 |
Why?
|
Female | 87 | 2025 | 30726 | 1.830 |
Why?
|
Heart Diseases | 3 | 2022 | 206 | 1.670 |
Why?
|
Humans | 125 | 2025 | 59389 | 1.650 |
Why?
|
Magnetic Resonance Imaging | 28 | 2022 | 2055 | 1.630 |
Why?
|
Diffusion Magnetic Resonance Imaging | 15 | 2021 | 145 | 1.600 |
Why?
|
Recovery of Function | 9 | 2019 | 270 | 1.550 |
Why?
|
Intracranial Thrombosis | 9 | 2024 | 27 | 1.530 |
Why?
|
Mechanical Thrombolysis | 4 | 2024 | 35 | 1.480 |
Why?
|
Venous Thrombosis | 7 | 2024 | 110 | 1.450 |
Why?
|
Armadillo Domain Proteins | 2 | 2025 | 22 | 1.430 |
Why?
|
Risk Factors | 31 | 2025 | 4986 | 1.420 |
Why?
|
Amyotrophic Lateral Sclerosis | 3 | 2025 | 480 | 1.410 |
Why?
|
National Institutes of Health (U.S.) | 3 | 2015 | 111 | 1.400 |
Why?
|
Carotid Artery, Internal, Dissection | 8 | 2025 | 15 | 1.390 |
Why?
|
Cytoskeletal Proteins | 2 | 2025 | 196 | 1.320 |
Why?
|
Brain Injuries | 4 | 2020 | 135 | 1.250 |
Why?
|
Ischemic Attack, Transient | 8 | 2024 | 90 | 1.240 |
Why?
|
Neuroimaging | 8 | 2022 | 143 | 1.200 |
Why?
|
Rats | 28 | 2018 | 1910 | 1.180 |
Why?
|
Long QT Syndrome | 2 | 2021 | 30 | 1.150 |
Why?
|
Carotid Stenosis | 3 | 2024 | 104 | 1.120 |
Why?
|
Time Factors | 25 | 2024 | 3617 | 1.060 |
Why?
|
Reperfusion | 7 | 2024 | 35 | 1.060 |
Why?
|
Animals | 48 | 2025 | 19650 | 1.050 |
Why?
|
Cost of Illness | 3 | 2015 | 156 | 1.010 |
Why?
|
Cortical Spreading Depression | 4 | 2020 | 7 | 1.010 |
Why?
|
Vertebral Artery Dissection | 5 | 2025 | 14 | 1.010 |
Why?
|
Brain Infarction | 5 | 2021 | 19 | 0.990 |
Why?
|
Frontotemporal Dementia | 2 | 2023 | 136 | 0.940 |
Why?
|
Superoxide Dismutase-1 | 1 | 2025 | 133 | 0.910 |
Why?
|
Pick Disease of the Brain | 1 | 2023 | 5 | 0.880 |
Why?
|
C9orf72 Protein | 2 | 2023 | 104 | 0.870 |
Why?
|
Geniculate Bodies | 1 | 2023 | 2 | 0.850 |
Why?
|
Predictive Value of Tests | 8 | 2024 | 1027 | 0.830 |
Why?
|
Axons | 3 | 2023 | 118 | 0.830 |
Why?
|
Tomography, X-Ray Computed | 9 | 2025 | 1507 | 0.800 |
Why?
|
Pancreatitis | 1 | 2023 | 95 | 0.790 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 206 | 0.780 |
Why?
|
Platelet Aggregation Inhibitors | 8 | 2025 | 211 | 0.760 |
Why?
|
Aspirin | 3 | 2022 | 167 | 0.760 |
Why?
|
Neurons | 6 | 2023 | 863 | 0.760 |
Why?
|
Chronic Traumatic Encephalopathy | 1 | 2021 | 5 | 0.740 |
Why?
|
Prognosis | 11 | 2024 | 1597 | 0.740 |
Why?
|
Tauopathies | 1 | 2021 | 18 | 0.730 |
Why?
|
Registries | 9 | 2025 | 801 | 0.720 |
Why?
|
Intracranial Embolism | 5 | 2014 | 39 | 0.710 |
Why?
|
Risk Assessment | 11 | 2024 | 1925 | 0.710 |
Why?
|
Troponin | 2 | 2020 | 36 | 0.700 |
Why?
|
Electroencephalography | 3 | 2020 | 134 | 0.700 |
Why?
|
Electrocardiography | 2 | 2021 | 523 | 0.680 |
Why?
|
Rats, Wistar | 12 | 2017 | 179 | 0.660 |
Why?
|
Vitamin K | 1 | 2019 | 14 | 0.650 |
Why?
|
Rats, Sprague-Dawley | 14 | 2010 | 574 | 0.650 |
Why?
|
Weight Loss | 1 | 2021 | 263 | 0.640 |
Why?
|
Cognition | 2 | 2022 | 454 | 0.640 |
Why?
|
Hematoma | 1 | 2019 | 68 | 0.630 |
Why?
|
Recurrence | 9 | 2025 | 602 | 0.620 |
Why?
|
Mice | 11 | 2025 | 10291 | 0.620 |
Why?
|
Leukoencephalopathies | 1 | 2019 | 24 | 0.610 |
Why?
|
Disability Evaluation | 4 | 2024 | 199 | 0.610 |
Why?
|
Adult | 23 | 2025 | 15681 | 0.610 |
Why?
|
Reperfusion Injury | 3 | 2021 | 49 | 0.600 |
Why?
|
Stroke Rehabilitation | 1 | 2019 | 46 | 0.600 |
Why?
|
Nucleic Acids | 1 | 2019 | 50 | 0.590 |
Why?
|
Diffuse Axonal Injury | 1 | 2018 | 4 | 0.590 |
Why?
|
Intracranial Hemorrhage, Traumatic | 1 | 2018 | 9 | 0.590 |
Why?
|
Hyperoxia | 2 | 2008 | 16 | 0.580 |
Why?
|
Warfarin | 4 | 2024 | 105 | 0.560 |
Why?
|
Lateral Ventricles | 1 | 2017 | 8 | 0.560 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2018 | 158 | 0.560 |
Why?
|
Length of Stay | 2 | 2019 | 776 | 0.550 |
Why?
|
Stroke Volume | 1 | 2018 | 314 | 0.540 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 257 | 0.540 |
Why?
|
Motor Activity | 2 | 2019 | 333 | 0.530 |
Why?
|
Cerebral Hemorrhage | 6 | 2020 | 85 | 0.530 |
Why?
|
Alzheimer Disease | 2 | 2022 | 679 | 0.520 |
Why?
|
Thrombophilia | 2 | 2020 | 14 | 0.520 |
Why?
|
Eligibility Determination | 1 | 2016 | 35 | 0.520 |
Why?
|
Hemorrhage | 7 | 2024 | 260 | 0.510 |
Why?
|
Cerebrum | 1 | 2015 | 16 | 0.500 |
Why?
|
Propensity Score | 3 | 2025 | 144 | 0.500 |
Why?
|
Time-to-Treatment | 1 | 2016 | 98 | 0.490 |
Why?
|
Stroke, Lacunar | 1 | 2015 | 3 | 0.490 |
Why?
|
Post-Concussion Syndrome | 1 | 2015 | 5 | 0.480 |
Why?
|
Embolization, Therapeutic | 2 | 2019 | 308 | 0.480 |
Why?
|
Myxoma | 1 | 2015 | 13 | 0.480 |
Why?
|
Embolism, Paradoxical | 1 | 2015 | 13 | 0.480 |
Why?
|
Foramen Ovale, Patent | 1 | 2015 | 13 | 0.470 |
Why?
|
Glasgow Outcome Scale | 1 | 2014 | 17 | 0.470 |
Why?
|
Vitamin D Deficiency | 1 | 2015 | 41 | 0.470 |
Why?
|
Heart Neoplasms | 1 | 2015 | 31 | 0.470 |
Why?
|
Critical Care | 1 | 2019 | 397 | 0.470 |
Why?
|
Patient Selection | 2 | 2016 | 465 | 0.460 |
Why?
|
Myocardial Infarction | 2 | 2024 | 863 | 0.450 |
Why?
|
Middle Cerebral Artery | 4 | 2018 | 46 | 0.450 |
Why?
|
Nervous System Diseases | 1 | 2015 | 104 | 0.440 |
Why?
|
Infarction | 3 | 2023 | 19 | 0.440 |
Why?
|
Arterial Occlusive Diseases | 2 | 2012 | 71 | 0.440 |
Why?
|
Vitamin D | 1 | 2015 | 132 | 0.440 |
Why?
|
Infarction, Posterior Cerebral Artery | 1 | 2013 | 7 | 0.440 |
Why?
|
Clinical Laboratory Techniques | 1 | 2014 | 43 | 0.440 |
Why?
|
Sinus Thrombosis, Intracranial | 2 | 2024 | 7 | 0.430 |
Why?
|
Cerebral Arterial Diseases | 2 | 2011 | 8 | 0.430 |
Why?
|
Temporal Lobe | 1 | 2013 | 46 | 0.430 |
Why?
|
Vertebrobasilar Insufficiency | 1 | 2013 | 23 | 0.430 |
Why?
|
Multivariate Analysis | 4 | 2017 | 902 | 0.420 |
Why?
|
Practice Patterns, Physicians' | 1 | 2019 | 692 | 0.420 |
Why?
|
Behavior, Animal | 4 | 2007 | 215 | 0.420 |
Why?
|
Mice, Knockout | 3 | 2025 | 1994 | 0.410 |
Why?
|
Venous Thromboembolism | 3 | 2024 | 145 | 0.410 |
Why?
|
Ultrasonography, Doppler, Transcranial | 1 | 2012 | 21 | 0.400 |
Why?
|
Brain Death | 1 | 2012 | 16 | 0.400 |
Why?
|
Stents | 3 | 2025 | 461 | 0.390 |
Why?
|
Neuroprotective Agents | 3 | 2009 | 72 | 0.380 |
Why?
|
Linear Models | 4 | 2020 | 403 | 0.380 |
Why?
|
Cell Death | 4 | 2007 | 271 | 0.380 |
Why?
|
Cohort Studies | 8 | 2024 | 2375 | 0.370 |
Why?
|
Anesthesia, General | 2 | 2024 | 43 | 0.370 |
Why?
|
Sex Characteristics | 1 | 2012 | 197 | 0.360 |
Why?
|
Coma | 1 | 2011 | 13 | 0.360 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2014 | 651 | 0.360 |
Why?
|
Heart Failure | 1 | 2018 | 853 | 0.360 |
Why?
|
Mice, Transgenic | 2 | 2025 | 1206 | 0.350 |
Why?
|
Laser-Doppler Flowmetry | 2 | 2018 | 6 | 0.350 |
Why?
|
Clinical Trials as Topic | 2 | 2019 | 440 | 0.340 |
Why?
|
Logistic Models | 4 | 2020 | 1234 | 0.340 |
Why?
|
Hemangioma, Cavernous, Central Nervous System | 1 | 2010 | 8 | 0.340 |
Why?
|
Maze Learning | 2 | 2007 | 50 | 0.330 |
Why?
|
Functional Laterality | 2 | 2007 | 133 | 0.330 |
Why?
|
United States | 8 | 2025 | 7426 | 0.330 |
Why?
|
Acute Disease | 3 | 2023 | 658 | 0.330 |
Why?
|
Central Nervous System Neoplasms | 1 | 2010 | 38 | 0.330 |
Why?
|
Mice, Inbred C57BL | 4 | 2021 | 3231 | 0.330 |
Why?
|
Meningeal Carcinomatosis | 1 | 2009 | 2 | 0.330 |
Why?
|
Head Injuries, Closed | 2 | 2021 | 14 | 0.320 |
Why?
|
Spatial Behavior | 2 | 2007 | 8 | 0.320 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 1022 | 0.320 |
Why?
|
Hyperbaric Oxygenation | 2 | 2006 | 16 | 0.320 |
Why?
|
Neuropsychological Tests | 2 | 2022 | 371 | 0.310 |
Why?
|
Prospective Studies | 5 | 2024 | 3067 | 0.310 |
Why?
|
Autophagy | 2 | 2021 | 213 | 0.310 |
Why?
|
Patient Admission | 3 | 2020 | 184 | 0.300 |
Why?
|
Disease Progression | 3 | 2025 | 1119 | 0.300 |
Why?
|
Age Factors | 5 | 2024 | 1504 | 0.300 |
Why?
|
Carcinoma | 1 | 2009 | 116 | 0.300 |
Why?
|
Esophageal Neoplasms | 1 | 2009 | 79 | 0.300 |
Why?
|
Analysis of Variance | 4 | 2015 | 589 | 0.290 |
Why?
|
Incidence | 5 | 2025 | 1238 | 0.290 |
Why?
|
Circle of Willis | 1 | 2007 | 7 | 0.290 |
Why?
|
Nerve Fibers | 1 | 2007 | 29 | 0.280 |
Why?
|
Electrophysiology | 1 | 2007 | 87 | 0.280 |
Why?
|
Discrimination Learning | 1 | 2007 | 11 | 0.280 |
Why?
|
Levodopa | 1 | 2007 | 8 | 0.280 |
Why?
|
Hyperhomocysteinemia | 1 | 2007 | 6 | 0.280 |
Why?
|
Nitrous Oxide | 1 | 2007 | 7 | 0.270 |
Why?
|
Hypotension | 1 | 2007 | 48 | 0.270 |
Why?
|
Radiography | 3 | 2019 | 516 | 0.270 |
Why?
|
Guidelines as Topic | 2 | 2019 | 154 | 0.270 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2007 | 35 | 0.270 |
Why?
|
DNA Repeat Expansion | 2 | 2023 | 53 | 0.260 |
Why?
|
Prevalence | 4 | 2020 | 1253 | 0.260 |
Why?
|
Proteasome Inhibitors | 1 | 2006 | 30 | 0.260 |
Why?
|
Cerebral Angiography | 4 | 2022 | 280 | 0.250 |
Why?
|
Biomarkers | 4 | 2020 | 1307 | 0.250 |
Why?
|
Boronic Acids | 1 | 2006 | 28 | 0.250 |
Why?
|
Hippocampus | 2 | 2007 | 246 | 0.250 |
Why?
|
Pyrazines | 1 | 2006 | 33 | 0.250 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 1091 | 0.250 |
Why?
|
Follow-Up Studies | 4 | 2022 | 2338 | 0.250 |
Why?
|
Blood Pressure | 4 | 2010 | 496 | 0.250 |
Why?
|
Brain Edema | 2 | 2021 | 31 | 0.250 |
Why?
|
Diffusion | 5 | 2010 | 82 | 0.250 |
Why?
|
Thromboembolism | 1 | 2006 | 69 | 0.250 |
Why?
|
Infarction, Anterior Cerebral Artery | 1 | 2025 | 3 | 0.250 |
Why?
|
Research | 1 | 2007 | 188 | 0.240 |
Why?
|
Tetrazolium Salts | 4 | 2009 | 15 | 0.240 |
Why?
|
Chi-Square Distribution | 2 | 2016 | 409 | 0.230 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2024 | 26 | 0.230 |
Why?
|
Nerve Tissue Proteins | 1 | 2007 | 418 | 0.230 |
Why?
|
Telemedicine | 1 | 2009 | 308 | 0.220 |
Why?
|
Conscious Sedation | 1 | 2024 | 38 | 0.220 |
Why?
|
Secondary Prevention | 2 | 2021 | 151 | 0.220 |
Why?
|
Echocardiography | 2 | 2018 | 457 | 0.220 |
Why?
|
Blood Glucose | 2 | 2020 | 461 | 0.220 |
Why?
|
Astrocytes | 2 | 2021 | 116 | 0.220 |
Why?
|
Elective Surgical Procedures | 1 | 2024 | 112 | 0.220 |
Why?
|
Epilepsy | 1 | 2024 | 105 | 0.220 |
Why?
|
Mortality | 2 | 2021 | 155 | 0.210 |
Why?
|
Skull | 1 | 2023 | 50 | 0.210 |
Why?
|
Endarterectomy, Carotid | 1 | 2024 | 91 | 0.210 |
Why?
|
Massachusetts | 2 | 2020 | 2019 | 0.210 |
Why?
|
Blindness | 1 | 2023 | 38 | 0.210 |
Why?
|
Cerebral Revascularization | 2 | 2024 | 30 | 0.210 |
Why?
|
Vision Disorders | 1 | 2023 | 59 | 0.200 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2022 | 21 | 0.200 |
Why?
|
Proof of Concept Study | 1 | 2022 | 35 | 0.200 |
Why?
|
Simvastatin | 1 | 2022 | 26 | 0.200 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2024 | 678 | 0.200 |
Why?
|
Administration, Oral | 2 | 2022 | 355 | 0.190 |
Why?
|
Rats, Inbred WKY | 3 | 2014 | 11 | 0.190 |
Why?
|
Dabigatran | 1 | 2022 | 20 | 0.190 |
Why?
|
Reflex | 1 | 2021 | 27 | 0.190 |
Why?
|
Arginine | 1 | 2022 | 110 | 0.190 |
Why?
|
DNA-Binding Proteins | 2 | 2023 | 1151 | 0.190 |
Why?
|
Statistics, Nonparametric | 2 | 2015 | 206 | 0.190 |
Why?
|
Mean Platelet Volume | 1 | 2020 | 2 | 0.180 |
Why?
|
Survival Analysis | 2 | 2016 | 554 | 0.170 |
Why?
|
Recombinant Proteins | 3 | 2020 | 689 | 0.170 |
Why?
|
Survival Rate | 3 | 2020 | 801 | 0.170 |
Why?
|
Hydrocephalus | 1 | 2020 | 43 | 0.170 |
Why?
|
Blood Coagulation | 1 | 2020 | 37 | 0.170 |
Why?
|
Bed Rest | 1 | 2019 | 10 | 0.170 |
Why?
|
Hyperglycemia | 1 | 2020 | 98 | 0.170 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2020 | 77 | 0.170 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 163 | 0.160 |
Why?
|
Subarachnoid Hemorrhage | 1 | 2020 | 93 | 0.160 |
Why?
|
CADASIL | 1 | 2019 | 3 | 0.160 |
Why?
|
Neurodegenerative Diseases | 1 | 2021 | 134 | 0.160 |
Why?
|
Neurologic Examination | 1 | 2019 | 52 | 0.160 |
Why?
|
Reproducibility of Results | 2 | 2024 | 1559 | 0.150 |
Why?
|
Betacoronavirus | 1 | 2020 | 166 | 0.150 |
Why?
|
Trauma Severity Indices | 1 | 2018 | 34 | 0.150 |
Why?
|
Attention | 1 | 2019 | 146 | 0.150 |
Why?
|
Random Allocation | 3 | 2007 | 192 | 0.150 |
Why?
|
Blood-Brain Barrier | 1 | 2018 | 81 | 0.150 |
Why?
|
Huntingtin Protein | 1 | 2018 | 138 | 0.140 |
Why?
|
Optical Imaging | 1 | 2018 | 68 | 0.140 |
Why?
|
Regional Blood Flow | 2 | 2008 | 108 | 0.140 |
Why?
|
Blood Vessel Prosthesis | 1 | 2019 | 215 | 0.140 |
Why?
|
Magnetic Resonance Angiography | 2 | 2011 | 178 | 0.140 |
Why?
|
Adolescent | 3 | 2023 | 5838 | 0.140 |
Why?
|
Coronavirus Infections | 1 | 2020 | 192 | 0.140 |
Why?
|
Activities of Daily Living | 1 | 2019 | 289 | 0.140 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 205 | 0.140 |
Why?
|
Neurosurgery | 1 | 2017 | 28 | 0.140 |
Why?
|
Neurology | 1 | 2017 | 33 | 0.130 |
Why?
|
Triage | 1 | 2017 | 108 | 0.130 |
Why?
|
Specialization | 1 | 2017 | 78 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2016 | 40 | 0.130 |
Why?
|
Wallerian Degeneration | 1 | 2016 | 8 | 0.130 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 931 | 0.130 |
Why?
|
Plasminogen Activators | 1 | 2015 | 10 | 0.130 |
Why?
|
Corpus Callosum | 1 | 2016 | 40 | 0.130 |
Why?
|
Cognition Disorders | 1 | 2017 | 215 | 0.120 |
Why?
|
Catheters | 1 | 2016 | 71 | 0.120 |
Why?
|
Pandemics | 1 | 2020 | 617 | 0.120 |
Why?
|
Patient Transfer | 1 | 2016 | 90 | 0.120 |
Why?
|
Immunohistochemistry | 3 | 2006 | 847 | 0.120 |
Why?
|
Hospitalization | 2 | 2020 | 1292 | 0.120 |
Why?
|
Intracranial Aneurysm | 1 | 2019 | 345 | 0.120 |
Why?
|
Software | 2 | 2009 | 366 | 0.120 |
Why?
|
Glasgow Coma Scale | 1 | 2014 | 43 | 0.120 |
Why?
|
Administration, Intravenous | 2 | 2025 | 61 | 0.120 |
Why?
|
Young Adult | 3 | 2022 | 4272 | 0.120 |
Why?
|
Oxygen | 3 | 2022 | 313 | 0.110 |
Why?
|
Odds Ratio | 1 | 2016 | 746 | 0.110 |
Why?
|
Neoplasms | 1 | 2024 | 1231 | 0.110 |
Why?
|
Injections, Intra-Arterial | 1 | 2014 | 20 | 0.110 |
Why?
|
Dementia | 1 | 2017 | 248 | 0.110 |
Why?
|
Bipolar Disorder | 1 | 2016 | 243 | 0.110 |
Why?
|
Amyloid beta-Peptides | 1 | 2016 | 286 | 0.110 |
Why?
|
Emergency Medical Services | 1 | 2017 | 255 | 0.110 |
Why?
|
Multiple Sclerosis | 1 | 2016 | 207 | 0.110 |
Why?
|
Intensive Care Units | 1 | 2017 | 423 | 0.110 |
Why?
|
Comorbidity | 3 | 2024 | 1078 | 0.110 |
Why?
|
ROC Curve | 1 | 2014 | 267 | 0.100 |
Why?
|
Research Design | 1 | 2016 | 555 | 0.100 |
Why?
|
Carotid-Cavernous Sinus Fistula | 1 | 2012 | 6 | 0.100 |
Why?
|
Regression Analysis | 1 | 2014 | 486 | 0.100 |
Why?
|
Technetium Tc 99m Exametazime | 1 | 2012 | 3 | 0.100 |
Why?
|
Nasopharynx | 1 | 2012 | 20 | 0.100 |
Why?
|
RNA, Small Interfering | 1 | 2018 | 858 | 0.100 |
Why?
|
Cooperative Behavior | 1 | 2014 | 210 | 0.100 |
Why?
|
Radiopharmaceuticals | 1 | 2012 | 181 | 0.090 |
Why?
|
Dysarthria | 1 | 2011 | 7 | 0.090 |
Why?
|
Teaching | 1 | 2012 | 152 | 0.090 |
Why?
|
Carotid Artery, Internal | 2 | 2024 | 66 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2022 | 300 | 0.090 |
Why?
|
Thalamus | 1 | 2011 | 64 | 0.090 |
Why?
|
New York City | 2 | 2020 | 75 | 0.090 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 205 | 0.090 |
Why?
|
Hospital Mortality | 2 | 2025 | 842 | 0.090 |
Why?
|
Reaction Time | 2 | 2007 | 119 | 0.080 |
Why?
|
Tomography Scanners, X-Ray Computed | 1 | 2009 | 13 | 0.080 |
Why?
|
Dogs | 2 | 2022 | 314 | 0.080 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2009 | 39 | 0.080 |
Why?
|
Quality of Life | 1 | 2016 | 1137 | 0.080 |
Why?
|
Magnetic Field Therapy | 1 | 2008 | 3 | 0.080 |
Why?
|
Computed Tomography Angiography | 2 | 2022 | 110 | 0.080 |
Why?
|
Ganglia, Parasympathetic | 1 | 2007 | 2 | 0.070 |
Why?
|
Cerebral Cortex | 2 | 2006 | 248 | 0.070 |
Why?
|
Injury Severity Score | 1 | 2007 | 101 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2009 | 169 | 0.070 |
Why?
|
Spectrum Analysis | 1 | 2007 | 51 | 0.070 |
Why?
|
Space Perception | 1 | 2007 | 19 | 0.070 |
Why?
|
Catechols | 1 | 2007 | 6 | 0.070 |
Why?
|
Homocysteine | 1 | 2007 | 33 | 0.070 |
Why?
|
Combined Modality Therapy | 2 | 2024 | 354 | 0.070 |
Why?
|
Silicon | 1 | 2006 | 19 | 0.070 |
Why?
|
Immunoassay | 1 | 2007 | 67 | 0.070 |
Why?
|
Sutures | 1 | 2006 | 35 | 0.070 |
Why?
|
Nitriles | 1 | 2007 | 62 | 0.070 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2009 | 229 | 0.070 |
Why?
|
Cerebral Arteries | 1 | 2007 | 39 | 0.070 |
Why?
|
Drug Interactions | 1 | 2007 | 115 | 0.070 |
Why?
|
Coloring Agents | 2 | 2023 | 53 | 0.070 |
Why?
|
Movement Disorders | 1 | 2006 | 22 | 0.070 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2007 | 57 | 0.070 |
Why?
|
Perfusion | 1 | 2006 | 79 | 0.070 |
Why?
|
Sensation Disorders | 1 | 2006 | 21 | 0.070 |
Why?
|
Autoradiography | 1 | 2006 | 53 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 705 | 0.060 |
Why?
|
Drug Therapy, Combination | 2 | 2022 | 451 | 0.060 |
Why?
|
Bortezomib | 1 | 2006 | 56 | 0.060 |
Why?
|
Down-Regulation | 1 | 2007 | 306 | 0.060 |
Why?
|
Surface Properties | 1 | 2006 | 271 | 0.060 |
Why?
|
Cell Count | 1 | 2005 | 127 | 0.060 |
Why?
|
Pregnancy | 2 | 2022 | 2213 | 0.060 |
Why?
|
Proteomics | 1 | 2007 | 263 | 0.060 |
Why?
|
Microtubule-Associated Proteins | 1 | 2005 | 111 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 347 | 0.060 |
Why?
|
Hypothermia, Induced | 1 | 2004 | 40 | 0.060 |
Why?
|
Heart Rate | 1 | 2005 | 307 | 0.060 |
Why?
|
Drug Administration Schedule | 1 | 2024 | 284 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2007 | 718 | 0.050 |
Why?
|
Delayed Diagnosis | 1 | 2023 | 42 | 0.050 |
Why?
|
Carotid Artery Diseases | 1 | 2024 | 63 | 0.050 |
Why?
|
Headache | 1 | 2023 | 54 | 0.050 |
Why?
|
Arteries | 1 | 2024 | 76 | 0.050 |
Why?
|
Intravital Microscopy | 1 | 2023 | 12 | 0.050 |
Why?
|
Tobacco Smoking | 1 | 2022 | 19 | 0.050 |
Why?
|
Collateral Circulation | 1 | 2022 | 22 | 0.050 |
Why?
|
Head | 1 | 2023 | 53 | 0.050 |
Why?
|
Antibodies, Antiphospholipid | 1 | 2022 | 11 | 0.050 |
Why?
|
Dipeptides | 1 | 2022 | 60 | 0.050 |
Why?
|
Feasibility Studies | 1 | 2024 | 526 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2024 | 180 | 0.050 |
Why?
|
Inpatients | 1 | 2024 | 292 | 0.050 |
Why?
|
Databases, Factual | 1 | 2024 | 814 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2022 | 297 | 0.050 |
Why?
|
Motor Neurons | 1 | 2022 | 203 | 0.050 |
Why?
|
Alberta | 1 | 2020 | 4 | 0.040 |
Why?
|
Patient Discharge | 1 | 2024 | 492 | 0.040 |
Why?
|
Patient Readmission | 1 | 2025 | 421 | 0.040 |
Why?
|
Mutation | 1 | 2009 | 2456 | 0.040 |
Why?
|
Postpartum Period | 1 | 2022 | 187 | 0.040 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 121 | 0.040 |
Why?
|
Blood Sedimentation | 1 | 2020 | 7 | 0.040 |
Why?
|
Ventriculoperitoneal Shunt | 1 | 2020 | 30 | 0.040 |
Why?
|
Cerebral Small Vessel Diseases | 1 | 2020 | 7 | 0.040 |
Why?
|
Risk Reduction Behavior | 1 | 2021 | 121 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 13 | 0.040 |
Why?
|
International Normalized Ratio | 1 | 2020 | 32 | 0.040 |
Why?
|
Migraine with Aura | 1 | 2020 | 1 | 0.040 |
Why?
|
Causality | 1 | 2020 | 57 | 0.040 |
Why?
|
Intracranial Arteriosclerosis | 1 | 2020 | 38 | 0.040 |
Why?
|
Drug Monitoring | 1 | 2020 | 115 | 0.040 |
Why?
|
Parkinson Disease | 1 | 2021 | 125 | 0.040 |
Why?
|
Dexamethasone | 1 | 2020 | 201 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 396 | 0.040 |
Why?
|
RNA | 1 | 2022 | 401 | 0.040 |
Why?
|
Glucose | 1 | 2022 | 445 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 674 | 0.040 |
Why?
|
Perfusion Imaging | 1 | 2018 | 18 | 0.040 |
Why?
|
Mannitol | 1 | 2018 | 14 | 0.040 |
Why?
|
CRISPR-Cas Systems | 1 | 2022 | 333 | 0.040 |
Why?
|
Docosahexaenoic Acids | 1 | 2018 | 30 | 0.040 |
Why?
|
Carotid Arteries | 1 | 2018 | 62 | 0.040 |
Why?
|
Phosphorylcholine | 1 | 2018 | 41 | 0.040 |
Why?
|
Smoking | 1 | 2022 | 826 | 0.040 |
Why?
|
Light | 1 | 2018 | 198 | 0.040 |
Why?
|
International Agencies | 1 | 2017 | 7 | 0.030 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 256 | 0.030 |
Why?
|
Hypercapnia | 2 | 2006 | 8 | 0.030 |
Why?
|
Interview, Psychological | 1 | 2016 | 73 | 0.030 |
Why?
|
Suction | 1 | 2016 | 33 | 0.030 |
Why?
|
Risk | 1 | 2017 | 364 | 0.030 |
Why?
|
Tertiary Care Centers | 1 | 2016 | 100 | 0.030 |
Why?
|
Gene Silencing | 1 | 2018 | 378 | 0.030 |
Why?
|
Catheter Ablation | 1 | 2017 | 145 | 0.030 |
Why?
|
Brain Mapping | 2 | 2007 | 228 | 0.030 |
Why?
|
Residence Characteristics | 1 | 2016 | 215 | 0.030 |
Why?
|
Societies, Medical | 1 | 2017 | 337 | 0.030 |
Why?
|
Equipment Design | 1 | 2016 | 329 | 0.030 |
Why?
|
Education, Medical, Graduate | 1 | 2017 | 317 | 0.030 |
Why?
|
Self Report | 1 | 2016 | 359 | 0.030 |
Why?
|
Curriculum | 1 | 2017 | 560 | 0.030 |
Why?
|
Hypercholesterolemia | 1 | 2012 | 68 | 0.020 |
Why?
|
Genetic Therapy | 1 | 2018 | 733 | 0.020 |
Why?
|
Fibrinolysis | 1 | 2011 | 5 | 0.020 |
Why?
|
Annexin A2 | 1 | 2011 | 6 | 0.020 |
Why?
|
Fibrin | 1 | 2011 | 18 | 0.020 |
Why?
|
Fibrinogen | 1 | 2011 | 31 | 0.020 |
Why?
|
Xenon Isotopes | 1 | 2010 | 3 | 0.020 |
Why?
|
Protons | 1 | 2010 | 60 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 2382 | 0.020 |
Why?
|
Proteinuria | 1 | 2009 | 38 | 0.020 |
Why?
|
Glomerulonephritis, Membranous | 1 | 2009 | 14 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2016 | 2516 | 0.020 |
Why?
|
Brain Damage, Chronic | 1 | 2006 | 5 | 0.020 |
Why?
|
Perceptual Disorders | 1 | 2006 | 8 | 0.020 |
Why?
|
Kidney | 1 | 2009 | 414 | 0.020 |
Why?
|
Sensation | 1 | 2006 | 19 | 0.020 |
Why?
|
Carbon Dioxide | 1 | 2006 | 81 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2009 | 357 | 0.020 |
Why?
|
Nerve Net | 1 | 2006 | 93 | 0.020 |
Why?
|
Psychomotor Performance | 1 | 2006 | 133 | 0.010 |
Why?
|
Phenotype | 1 | 2009 | 1137 | 0.010 |
Why?
|
Species Specificity | 1 | 2005 | 329 | 0.010 |
Why?
|
Atmosphere Exposure Chambers | 1 | 2004 | 2 | 0.010 |
Why?
|
Ischemia | 1 | 2005 | 199 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2004 | 279 | 0.010 |
Why?
|